Abstract
Enoxacin is a potent quinolone derivative with marked activity against gram-negative bacteria and staphylococci. The oral preparation has a potential role in treatment of gram-negative-bacterial lower respiratory infections if found to give adequate bronchial (sputum) concentrations. A study was done to determine the concomitant serum and bronchial concentrations of oral enoxacin after dosing with 600 mg, single dose; 400 mg, single dose; and 400 mg every 12 h, four doses. Blood and bronchial secretions were collected from 20 patients predose and 2, 5, and 9 h postdose. Bronchial secretions were obtained from tracheostomies, endotracheal tubes, or bronchoscopy. Levels of enoxacin in serum and sputum were measured by high-pressure liquid chromatography. Mean peak bronchial secretion levels were similar for the 400-mg dose schedules (2.2 and 2.4 micrograms/ml) but were significantly higher with the 600-mg dose (4.0 micrograms/ml) (P less than 0.05). Significant concentrations in bronchial secretions were still achievable at 9 h postdose (1.3 to 2.3 micrograms of enoxacin per ml). The mean ratios of enoxacin concentrations in sputum to those in serum at various time intervals for all groups were as follows: at 2 h, 0.55 +/- 0.34; at 5 h, 1.04 +/- 0.72; at 9 h, 0.97 +/- 0.62. Considering that most gram-negative bacteria are inhibited by 1.0 microgram of enoxacin per ml in vitro, this study shows that oral enoxacin in practical doses achieves a concentration in bronchial secretions that is adequate to treat most gram-negative-bacterial lower respiratory infections.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bauernfeind A., Ullmann U. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):33–38. doi: 10.1093/jac/14.suppl_c.33. [DOI] [PubMed] [Google Scholar]
- Chartrand S. A., Scribner R. K., Weber A. H., Welch D. F., Marks M. I. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound. Antimicrob Agents Chemother. 1983 May;23(5):658–663. doi: 10.1128/aac.23.5.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies B. I., Maesen F. P., Teengs J. P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):83–89. doi: 10.1093/jac/14.suppl_c.83. [DOI] [PubMed] [Google Scholar]
- Fong I. W., Ledbetter W. H., Vandenbroucke A. C., Simbul M., Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother. 1986 Mar;29(3):405–408. doi: 10.1128/aac.29.3.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klastersky J., Carpentier-Meunier F., Kahan-Coppens L., Thys J. P. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest. 1979 May;75(5):586–591. doi: 10.1378/chest.75.5.586. [DOI] [PubMed] [Google Scholar]
- Nakamura S., Minami A., Katae H., Inoue S., Yamagishi J., Takase Y., Shimizu M. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother. 1983 May;23(5):641–648. doi: 10.1128/aac.23.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Odio W., Van Laer E., Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol. 1975 Jul;15(7):518–524. doi: 10.1002/j.1552-4604.1975.tb01474.x. [DOI] [PubMed] [Google Scholar]
- Ruckdeschel G., Ehret W., Ahl A. Susceptibility of Legionella spp. to quinolone derivatives and related organic acids. Eur J Clin Microbiol. 1984 Aug;3(4):373–373. doi: 10.1007/BF01977502. [DOI] [PubMed] [Google Scholar]
- Siporin C., Towse G. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):47–55. doi: 10.1093/jac/14.suppl_c.47. [DOI] [PubMed] [Google Scholar]
- Wolf R., Eberl R., Dunky A., Mertz N., Chang T., Goulet J. R., Latts J. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):63–69. doi: 10.1093/jac/14.suppl_c.63. [DOI] [PubMed] [Google Scholar]